How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "8387"
  ["article_id"]=>
  string(4) "8387"
  [1]=>
  string(60) "Pfizer, BioNTech collaborate to develop vaccine for COVID-19"
  ["article_title"]=>
  string(60) "Pfizer, BioNTech collaborate to develop vaccine for COVID-19"
  [2]=>
  string(150) "Under material transfer and collaboration agreement, the companies will co-develop and supply potential mRNA-based coronavirus vaccine for the prevent"
  ["short_description"]=>
  string(150) "Under material transfer and collaboration agreement, the companies will co-develop and supply potential mRNA-based coronavirus vaccine for the prevent"
  [3]=>
  string(574) "
Under material transfer and collaboration agreement, the companies will co-develop and supply potential mRNA-based coronavirus vaccine for the prevention of COVID-19 infection. The vaccine will not be supplied 
&#nl
The post Pfizer, BioNTech collaborate to develop vaccine for COVID-19 appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(574) "
Under material transfer and collaboration agreement, the companies will co-develop and supply potential mRNA-based coronavirus vaccine for the prevention of COVID-19 infection. The vaccine will not be supplied 
&#nl
The post Pfizer, BioNTech collaborate to develop vaccine for COVID-19 appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(85) "https://www.pharmaceutical-business-review.com/news/pfizer-biontech-vaccine-covid-19/"
  ["blog_url"]=>
  string(85) "https://www.pharmaceutical-business-review.com/news/pfizer-biontech-vaccine-covid-19/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:18"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Pfizer, BioNTech collaborate to develop vaccine for COVID-19

Under material transfer and collaboration agreement, the companies will co-develop and supply potential mRNA-based co

array(40) {
  [0]=>
  string(4) "8388"
  ["article_id"]=>
  string(4) "8388"
  [1]=>
  string(71) "Moderna doses first patient with mRNA-1273 in coronavirus vaccine trial"
  ["article_title"]=>
  string(71) "Moderna doses first patient with mRNA-1273 in coronavirus vaccine trial"
  [2]=>
  string(155) "Moderna has announced the dosing of the first participant in a phase1 study of mRNA-1273, the company’s mRNA vaccine candidate against the novel cor"
  ["short_description"]=>
  string(155) "Moderna has announced the dosing of the first participant in a phase1 study of mRNA-1273, the company’s mRNA vaccine candidate against the novel cor"
  [3]=>
  string(578) "
Moderna has announced the dosing of the first participant in a phase1 study of mRNA-1273, the company’s mRNA vaccine candidate against the novel coronavirus (SARS-CoV-2). The early-stage study 
&#nl
The post Moderna doses first patient with mRNA-1273 in coronavirus vaccine trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(578) "
Moderna has announced the dosing of the first participant in a phase1 study of mRNA-1273, the company’s mRNA vaccine candidate against the novel coronavirus (SARS-CoV-2). The early-stage study 
&#nl
The post Moderna doses first patient with mRNA-1273 in coronavirus vaccine trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(88) "https://www.pharmaceutical-business-review.com/news/moderna-mrna-1273-coronavirus-trial/"
  ["blog_url"]=>
  string(88) "https://www.pharmaceutical-business-review.com/news/moderna-mrna-1273-coronavirus-trial/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:18"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Moderna doses first patient with mRNA-1273 in coronavirus vaccine trial

Moderna has announced the dosing of the first participant in a phase1 study of mRNA-1273, the company’s mRNA v

array(40) {
  [0]=>
  string(4) "8389"
  ["article_id"]=>
  string(4) "8389"
  [1]=>
  string(125) "Aurinia initiates rolling submission of a new drug application to the FDA for Voclosporin in the treatment of lupus nephritis"
  ["article_title"]=>
  string(125) "Aurinia initiates rolling submission of a new drug application to the FDA for Voclosporin in the treatment of lupus nephritis"
  [2]=>
  string(150) "The rolling NDA allows completed portions of an NDA to be submitted and reviewed by the Agency on an ongoing basis. Aurinia has submitted the Nonclini"
  ["short_description"]=>
  string(150) "The rolling NDA allows completed portions of an NDA to be submitted and reviewed by the Agency on an ongoing basis. Aurinia has submitted the Nonclini"
  [3]=>
  string(687) "
The rolling NDA allows completed portions of an NDA to be submitted and reviewed by the Agency on an ongoing basis. Aurinia has submitted the Nonclinical Module and 
&#nl
The post Aurinia initiates rolling submission of a new drug application to the FDA for Voclosporin in the treatment of lupus nephritis appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(687) "
The rolling NDA allows completed portions of an NDA to be submitted and reviewed by the Agency on an ongoing basis. Aurinia has submitted the Nonclinical Module and 
&#nl
The post Aurinia initiates rolling submission of a new drug application to the FDA for Voclosporin in the treatment of lupus nephritis appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(178) "https://www.pharmaceutical-business-review.com/news/aurinia-initiates-rolling-submission-of-a-new-drug-application-to-the-fda-for-voclosporin-in-the-treatment-of-lupus-nephritis/"
  ["blog_url"]=>
  string(178) "https://www.pharmaceutical-business-review.com/news/aurinia-initiates-rolling-submission-of-a-new-drug-application-to-the-fda-for-voclosporin-in-the-treatment-of-lupus-nephritis/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:18"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Aurinia initiates rolling submission of a new drug application to the FDA for Voclosporin

The rolling NDA allows completed portions of an NDA to be submitted and reviewed by the Agency on an ongoing basis. A

array(40) {
  [0]=>
  string(4) "8390"
  ["article_id"]=>
  string(4) "8390"
  [1]=>
  string(60) "AcelRx Pharmaceuticals to acquire Tetraphase Pharmaceuticals"
  ["article_title"]=>
  string(60) "AcelRx Pharmaceuticals to acquire Tetraphase Pharmaceuticals"
  [2]=>
  string(156) "The CVR represents additional consideration upon XERAVA™ (eravacycline for injection) achieving certain net sales starting in 2021.  The acquisitio"
  ["short_description"]=>
  string(156) "The CVR represents additional consideration upon XERAVA™ (eravacycline for injection) achieving certain net sales starting in 2021.  The acquisitio"
  [3]=>
  string(613) "
The CVR represents additional consideration upon XERAVAâ„¢ (eravacycline for injection) achieving certain net sales starting in 2021.  The acquisition is consistent with AcelRx’s strategic plan to expand and 
&#nl
The post AcelRx Pharmaceuticals to acquire Tetraphase Pharmaceuticals appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(613) "
The CVR represents additional consideration upon XERAVAâ„¢ (eravacycline for injection) achieving certain net sales starting in 2021.  The acquisition is consistent with AcelRx’s strategic plan to expand and 
&#nl
The post AcelRx Pharmaceuticals to acquire Tetraphase Pharmaceuticals appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(113) "https://www.pharmaceutical-business-review.com/news/acelrx-pharmaceuticals-to-acquire-tetraphase-pharmaceuticals/"
  ["blog_url"]=>
  string(113) "https://www.pharmaceutical-business-review.com/news/acelrx-pharmaceuticals-to-acquire-tetraphase-pharmaceuticals/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:18"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

AcelRx Pharmaceuticals to acquire Tetraphase Pharmaceuticals

The CVR represents additional consideration upon XERAVAâ„¢ (eravacycline for injection) achieving certain net sal

array(40) {
  [0]=>
  string(4) "8391"
  ["article_id"]=>
  string(4) "8391"
  [1]=>
  string(90) "Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata"
  ["article_title"]=>
  string(90) "Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata"
  [2]=>
  string(150) "AA is an autoimmune disorder, which may result in an unpredictable hair loss on the scalp, face and other areas of the body. The FDA has provided the "
  ["short_description"]=>
  string(150) "AA is an autoimmune disorder, which may result in an unpredictable hair loss on the scalp, face and other areas of the body. The FDA has provided the "
  [3]=>
  string(536) "
AA is an autoimmune disorder, which may result in an unpredictable hair loss on the scalp, face and other areas of the body. The FDA has provided the 
&#nl
The post Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(536) "
AA is an autoimmune disorder, which may result in an unpredictable hair loss on the scalp, face and other areas of the body. The FDA has provided the 
&#nl
The post Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(77) "https://www.pharmaceutical-business-review.com/news/lilly-incyte-baricitinib/"
  ["blog_url"]=>
  string(77) "https://www.pharmaceutical-business-review.com/news/lilly-incyte-baricitinib/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:18"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata

AA is an autoimmune disorder, which may result in an unpredictable hair loss on the scalp, face and other areas of th

array(40) {
  [0]=>
  string(4) "8392"
  ["article_id"]=>
  string(4) "8392"
  [1]=>
  string(119) "BioStem Life Sciences announces expansion; contract manufacturing capabilities, and research and development laboratory"
  ["article_title"]=>
  string(119) "BioStem Life Sciences announces expansion; contract manufacturing capabilities, and research and development laboratory"
  [2]=>
  string(150) "Situated in the Company’s 6,100 sq. Ft., state-of-the-art, FDA registered, cGMP facility, this new lab will support the research and development"
  ["short_description"]=>
  string(150) "Situated in the Company’s 6,100 sq. Ft., state-of-the-art, FDA registered, cGMP facility, this new lab will support the research and development"
  [3]=>
  string(721) "
Situated in the Company’s 6,100 sq. Ft., state-of-the-art, FDA registered, cGMP facility, this new lab will support the research and development pipeline for the Company’s growing Contract Development 
&#nl
The post BioStem Life Sciences announces expansion; contract manufacturing capabilities, and research and development laboratory appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(721) "
Situated in the Company’s 6,100 sq. Ft., state-of-the-art, FDA registered, cGMP facility, this new lab will support the research and development pipeline for the Company’s growing Contract Development 
&#nl
The post BioStem Life Sciences announces expansion; contract manufacturing capabilities, and research and development laboratory appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(170) "https://www.pharmaceutical-business-review.com/news/biostem-life-sciences-announces-expansion-contract-manufacturing-capabilities-and-research-and-development-laboratory/"
  ["blog_url"]=>
  string(170) "https://www.pharmaceutical-business-review.com/news/biostem-life-sciences-announces-expansion-contract-manufacturing-capabilities-and-research-and-development-laboratory/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:19"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

BioStem Life Sciences announces expansion; contract manufacturing capabilities, and resear

Situated in the Company’s 6,100 sq. Ft., state-of-the-art, FDA registered, cGMP facility, this new lab will sup

array(40) {
  [0]=>
  string(4) "8393"
  ["article_id"]=>
  string(4) "8393"
  [1]=>
  string(137) "Can-Fite to explore the anti-coronavirus effects of piclidenoson in collaboration with Lewis Katz School of Medicine at Temple University"
  ["article_title"]=>
  string(137) "Can-Fite to explore the anti-coronavirus effects of piclidenoson in collaboration with Lewis Katz School of Medicine at Temple University"
  [2]=>
  string(150) "The agreement will support research directed by Dr. Kamel Khalili, aimed to explore anti-viral activity of Piclidenoson on Coronaviruses viral load in"
  ["short_description"]=>
  string(150) "The agreement will support research directed by Dr. Kamel Khalili, aimed to explore anti-viral activity of Piclidenoson on Coronaviruses viral load in"
  [3]=>
  string(730) "
The agreement will support research directed by Dr. Kamel Khalili, aimed to explore anti-viral activity of Piclidenoson on Coronaviruses viral load in a mammalian cell model system as 
&#nl
The post Can-Fite to explore the anti-coronavirus effects of piclidenoson in collaboration with Lewis Katz School of Medicine at Temple University appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(730) "
The agreement will support research directed by Dr. Kamel Khalili, aimed to explore anti-viral activity of Piclidenoson on Coronaviruses viral load in a mammalian cell model system as 
&#nl
The post Can-Fite to explore the anti-coronavirus effects of piclidenoson in collaboration with Lewis Katz School of Medicine at Temple University appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(190) "https://www.pharmaceutical-business-review.com/news/can-fite-to-explore-the-anti-coronavirus-effects-of-piclidenoson-in-collaboration-with-lewis-katz-school-of-medicine-at-temple-university/"
  ["blog_url"]=>
  string(190) "https://www.pharmaceutical-business-review.com/news/can-fite-to-explore-the-anti-coronavirus-effects-of-piclidenoson-in-collaboration-with-lewis-katz-school-of-medicine-at-temple-university/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:19"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Can-Fite to explore the anti-coronavirus effects of piclidenoson in collaboration with Lew

The agreement will support research directed by Dr. Kamel Khalili, aimed to explore anti-viral activity of Piclidenos

array(40) {
  [0]=>
  string(4) "8469"
  ["article_id"]=>
  string(4) "8469"
  [1]=>
  string(165) "Leaders in cybersecurity have united to combat an unprecedented level of cyberattacks particularly targeting the healthcare sector in the wake of the Covid-19 crisis"
  ["article_title"]=>
  string(165) "Leaders in cybersecurity have united to combat an unprecedented level of cyberattacks particularly targeting the healthcare sector in the wake of the Covid-19 crisis"
  [2]=>
  string(150) "The Alliance – including ITC Secure, IronNet, Haven Cyber Technologies, Enveil, 4iQ and Blue Cedar – has been established by C5 Capital, t"
  ["short_description"]=>
  string(150) "The Alliance – including ITC Secure, IronNet, Haven Cyber Technologies, Enveil, 4iQ and Blue Cedar – has been established by C5 Capital, t"
  [3]=>
  string(542) "The Alliance – including ITC Secure, IronNet, Haven Cyber Technologies, Enveil, 4iQ and Blue Cedar – has been established by C5 Capital, the specialist investment firm. Its first action is to provide key healthcare and research facilities with free access to a state-of-the-art cybersecurity solution through the Collective Cyber Defence for Healthcare initiative The initiative follows a more than doubling of cyberattacks on the global healthcare sector in the last two months. Attackers have targeted...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(542) "The Alliance – including ITC Secure, IronNet, Haven Cyber Technologies, Enveil, 4iQ and Blue Cedar – has been established by C5 Capital, the specialist investment firm. Its first action is to provide key healthcare and research facilities with free access to a state-of-the-art cybersecurity solution through the Collective Cyber Defence for Healthcare initiative The initiative follows a more than doubling of cyberattacks on the global healthcare sector in the last two months. Attackers have targeted...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "64"
  ["rss_id"]=>
  string(2) "64"
  [14]=>
  string(107) "https://www.realwire.com/releases/Leaders-in-cybersecurity-have-united-to-combat-unprecedented-cyberattacks"
  ["blog_url"]=>
  string(107) "https://www.realwire.com/releases/Leaders-in-cybersecurity-have-united-to-combat-unprecedented-cyberattacks"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:50"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Leaders in cybersecurity have united to combat an unprecedented level of cyberattacks part

The Alliance – including ITC Secure, IronNet, Haven Cyber Technologies, Enveil, 4iQ and Blue Cedar – has bee

array(40) {
  [0]=>
  string(4) "8470"
  ["article_id"]=>
  string(4) "8470"
  [1]=>
  string(108) "e-days partners with Doctor Care Anywhere so businesses can direct employees straight to virtual GP services"
  ["article_title"]=>
  string(108) "e-days partners with Doctor Care Anywhere so businesses can direct employees straight to virtual GP services"
  [2]=>
  string(150) "- New partnership first of its kind to link absence management systems to on-demand medical healthcare and advice- As Coronavirus spreads, Doctor Care"
  ["short_description"]=>
  string(150) "- New partnership first of its kind to link absence management systems to on-demand medical healthcare and advice- As Coronavirus spreads, Doctor Care"
  [3]=>
  string(544) "- New partnership first of its kind to link absence management systems to on-demand medical healthcare and advice- As Coronavirus spreads, Doctor Care Anywhere fielding hundreds of calls per day, relieving pressure on NHS London, UK: 17th March 2020: Employees can now access virtual GP services via their company’s absence management system, following a partnership between e-days, the leader in global absence intelligence, and Doctor Care Anywhere. The announcement sees e-days, the global absence management...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(544) "- New partnership first of its kind to link absence management systems to on-demand medical healthcare and advice- As Coronavirus spreads, Doctor Care Anywhere fielding hundreds of calls per day, relieving pressure on NHS London, UK: 17th March 2020: Employees can now access virtual GP services via their company’s absence management system, following a partnership between e-days, the leader in global absence intelligence, and Doctor Care Anywhere. The announcement sees e-days, the global absence management...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "4"
  ["category"]=>
  string(1) "4"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "65"
  ["rss_id"]=>
  string(2) "65"
  [14]=>
  string(75) "https://www.realwire.com/releases/e-days-partners-with-Doctor-Care-Anywhere"
  ["blog_url"]=>
  string(75) "https://www.realwire.com/releases/e-days-partners-with-Doctor-Care-Anywhere"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:52"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:52"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

e-days partners with Doctor Care Anywhere so businesses can direct employees straight to v

- New partnership first of its kind to link absence management systems to on-demand medical healthcare and advice- As Co

array(40) {
  [0]=>
  string(4) "8635"
  ["article_id"]=>
  string(4) "8635"
  [1]=>
  string(66) "Merck’s vericiguat meets primary endpoint in VICTORIA trial"
  ["article_title"]=>
  string(66) "Merck’s vericiguat meets primary endpoint in VICTORIA trial"
  [2]=>
  string(150) "Compared to placebo, vericiguat in combination with available heart failure therapies, significantly cut down the risk of heart failure hospitalisatio"
  ["short_description"]=>
  string(150) "Compared to placebo, vericiguat in combination with available heart failure therapies, significantly cut down the risk of heart failure hospitalisatio"
  [3]=>
  string(577) "
Compared to placebo, vericiguat in combination with available heart failure therapies, significantly cut down the risk of heart failure hospitalisation or cardiovascular death, which was the primary endpoint 
&#nl
The post Merck’s vericiguat meets primary endpoint in VICTORIA trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(577) "
Compared to placebo, vericiguat in combination with available heart failure therapies, significantly cut down the risk of heart failure hospitalisation or cardiovascular death, which was the primary endpoint 
&#nl
The post Merck’s vericiguat meets primary endpoint in VICTORIA trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(84) "https://www.pharmaceutical-business-review.com/news/merck-vericiguat-victoria-trial/"
  ["blog_url"]=>
  string(84) "https://www.pharmaceutical-business-review.com/news/merck-vericiguat-victoria-trial/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:27"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Merck’s vericiguat meets primary endpoint in VICTORIA trial

Compared to placebo, vericiguat in combination with available heart failure therapies, significantly cut down the ris

array(40) {
  [0]=>
  string(4) "8636"
  ["article_id"]=>
  string(4) "8636"
  [1]=>
  string(113) "AVEO Oncology and Biodesix to discontinue CyFi-2 study of ficlatuzumab in AML in response to public health crisis"
  ["article_title"]=>
  string(113) "AVEO Oncology and Biodesix to discontinue CyFi-2 study of ficlatuzumab in AML in response to public health crisis"
  [2]=>
  string(150) "This decision is being taken due to the urgent shift among clinical sites toward efforts to combat the COVID-19 pandemic, which has impacted the feasi"
  ["short_description"]=>
  string(150) "This decision is being taken due to the urgent shift among clinical sites toward efforts to combat the COVID-19 pandemic, which has impacted the feasi"
  [3]=>
  string(673) "
This decision is being taken due to the urgent shift among clinical sites toward efforts to combat the COVID-19 pandemic, which has impacted the feasibility of completing the 
&#nl
The post AVEO Oncology and Biodesix to discontinue CyFi-2 study of ficlatuzumab in AML in response to public health crisis appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(673) "
This decision is being taken due to the urgent shift among clinical sites toward efforts to combat the COVID-19 pandemic, which has impacted the feasibility of completing the 
&#nl
The post AVEO Oncology and Biodesix to discontinue CyFi-2 study of ficlatuzumab in AML in response to public health crisis appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(166) "https://www.pharmaceutical-business-review.com/news/aveo-oncology-and-biodesix-to-discontinue-cyfi-2-study-of-ficlatuzumab-in-aml-in-response-to-public-health-crisis/"
  ["blog_url"]=>
  string(166) "https://www.pharmaceutical-business-review.com/news/aveo-oncology-and-biodesix-to-discontinue-cyfi-2-study-of-ficlatuzumab-in-aml-in-response-to-public-health-crisis/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:27"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

AVEO Oncology and Biodesix to discontinue CyFi-2 study of ficlatuzumab in AML in response

This decision is being taken due to the urgent shift among clinical sites toward efforts to combat the COVID-19 pande

array(40) {
  [0]=>
  string(4) "8637"
  ["article_id"]=>
  string(4) "8637"
  [1]=>
  string(73) "FDA accepts Roche’s NDA for Xofluza to treat influenza in children"
  ["article_title"]=>
  string(73) "FDA accepts Roche’s NDA for Xofluza to treat influenza in children"
  [2]=>
  string(150) "The FDA accepted a NDA for a new formulation of Xofluza as one-dose granules for oral suspension (2 mg/mL), potentially offering a more convenient opt"
  ["short_description"]=>
  string(150) "The FDA accepted a NDA for a new formulation of Xofluza as one-dose granules for oral suspension (2 mg/mL), potentially offering a more convenient opt"
  [3]=>
  string(581) "
The FDA accepted a NDA for a new formulation of Xofluza as one-dose granules for oral suspension (2 mg/mL), potentially offering a more convenient option for children and 
&#nl
The post FDA accepts Roche’s NDA for Xofluza to treat influenza in children appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(581) "
The FDA accepted a NDA for a new formulation of Xofluza as one-dose granules for oral suspension (2 mg/mL), potentially offering a more convenient option for children and 
&#nl
The post FDA accepts Roche’s NDA for Xofluza to treat influenza in children appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(118) "https://www.pharmaceutical-business-review.com/news/fda-accepts-roches-nda-for-xofluza-to-treat-influenza-in-children/"
  ["blog_url"]=>
  string(118) "https://www.pharmaceutical-business-review.com/news/fda-accepts-roches-nda-for-xofluza-to-treat-influenza-in-children/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:27"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA accepts Roche’s NDA for Xofluza to treat influenza in children

The FDA accepted a NDA for a new formulation of Xofluza as one-dose granules for oral suspension (2 mg/mL), potential